Clinical trial
Safety and Efficacy of OP2000 (Deligoparin) in the Treatment of Active…
NCT00033943 · Incara Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00033943 |
|---|---|
| Title | Safety and Efficacy of OP2000 (Deligoparin) in the Treatment of Active Ulcerative Colitis |
| Official title | A Multi-Center, Placebo-Controlled Evaluation of the Safety and Efficacy of Two Dosage Levels of OP2000 (75 Mg and 125 Mg) Administered Once Daily by Subcutaneous Injection for the Treatment of Active Ulcerative Colitis |
| Lead sponsor | Incara Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 2/Phase 3 |
| Study type | Interventional |
| Conditions | Ulcerative Colitis |
| Intervention type | Drug |
| Interventions | deligoparin |
| Enrollment | 270 |
| Start date | Jan 1, 2001 |
| Completion | Sep 1, 2002 |
| First posted | Apr 17, 2002 |
| Last update posted | Jun 24, 2005 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: